CULT Food Science Congratulates Venture Arm Company De Novo Foodlabs on Seed Round Success and Progress with NanoFerrin™ Protein

TORONTO, / - CULT Food Science Corp. ("CULT" or the "Company") (CSE: CULT) (OTC: CULTF) (FRA: LN00), a disruptive food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry, proudly recognizes De Novo Foodlabs ("De Novo") for successfully closing their seed funding round and advancing the commercialization of their revolutionary precision fermented lactoferrin product, NanoFerrin™.

Key Takeaways:

• De Novo Foodlabs secured $1.5M in funding from Joyful Ventures, bringing its total funds raised to $4M.
   
• Joyful Ventures launched in 2023 and raised $23M from leaders in the alternative protein industry. Joyful Ventures is led by Vegan Women Summit's Jennifer Stojkovic, Good Food Institute co-founder Milo Runkle, and Student Brands' Blaine Vess. Among its advisors and investors are Oatly co-founder Björn Öste, Shiok Meats co-founder Sandhya Sriram, The Every Company CEO Arturo Elizondo, and Wild Earth CEO Ryan Bethencourt.
   
• The fresh capital will accelerate the commercialization of NanoFerrin™, an animal-free alternative to bovine lactoferrin, in the U.S.
   
• NanoFerrin™ provides key health benefits like improved immunity and longevity without the ethical and sustainability challenges of traditional lactoferrin production.

Lactoferrin, a functional protein primarily found in milk, plays a crucial role in infant development, and offers numerous health benefits for adults, such as improved immunity, brain health, iron absorption, gut health, and longevity. Lactoferrin has been shown to be effective in alleviating aging-related changes through its anti-oxidation, anti-cellular senescence, and anti-inflammation properties.¹ Traditional extraction methods from cow milk are not only prohibitively expensive but also plagued by sustainability and ethical challenges.

De Novo Foodlabs' NanoFerrin™ utilizes precision fermentation technology to produce a more affordable and sustainable alternative to bovine lactoferrin. The product is designed to meet growing demand across food, beverage, and supplements sectors, offering key health benefits such as enhanced iron absorption, gut health, and anti-aging properties. The global lactoferrin market, valued at $773M in 2023, is projected to grow annually by 15.8% over the next decade and De Novo is poised for rapid growth and market expansion with NanoFerrin™.²